[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[2]
|
He, R., Zhu, B., Liu, J., Zhang, N., Zhang, W.-H. and Mao, Y. (2021) Women’s Cancers in China: A Spatio-Temporal Epidemiology Analysis. BMC Women’s Health, 21, Article No. 116. https://doi.org/10.1186/s12905-021-01260-1
|
[3]
|
张国楠. 重视与践行卵巢癌的规范化治疗和全程管理[J]. 肿瘤预防与治疗, 2020, 33(5): 377-382.
|
[4]
|
Chang, S.J., Hodeib, M., Chang, J. and Bristow, R.E. (2013) Survival Im-pact of Complete Cytoreduction to No Gross Residual Disease for Advanced-Stage Ovarian Cancer: A Meta-Analysis. Gynecologic Oncology, 130, 493-498.
https://doi.org/10.1016/j.ygyno.2013.05.040
|
[5]
|
Lim, M.C., Yoo, H.J., Song, Y.J., et al. (2017) Survival Out-comes after Extensive Cytoreductive Surgery and Selective Neoadjuvant Chemotherapy According to Institutional Criteria in Bulky Stage IIIC and IV Epithelial Ovarian Cancer. Journal of Gynecologic Oncology, 28, e48. https://doi.org/10.3802/jgo.2017.28.e48
|
[6]
|
Bartels, H.C., Rogers, A.C., McSharry, V., et al. (2019) A Me-ta-Analysis of Morbidity and Mortality in Primary Cytoreductive Surgery Compared to Neoadjuvant Chemotherapy in Advanced Ovarian Malignancy. Gynecologic Oncology, 154, 622-630. https://doi.org/10.1016/j.ygyno.2019.07.011
|
[7]
|
Onda, T., Satoh, T., Saito, T., et al. (2016) Comparison of Treatment Invasiveness between Upfront Debulking Surgery Versus Interval Debulking Surgery Following Neoadjuvant Chemotherapy for Stage III/IV Ovarian, Tubal and Peritoneal Cancers in a Phase III Randomised Trial: Japan Clinical Oncology Group Study JCOG0602. European Journal of Cancer, 64, 22-31. https://doi.org/10.1016/j.ejca.2016.05.017
|
[8]
|
Kehoe, S., Hook, J., Nankivell, M., et al. (2015) Primary Chemo-therapy Versus Primary Surgery for Newly Diagnosed Advanced Ovarian Cancer (CHORUS): An Open-Label, Ran-domised, Controlled, Non-Inferiority Trial. The Lancet, 386, 249-257. https://doi.org/10.1016/S0140-6736(14)62223-6
|
[9]
|
Fagotti, A., Ferrandina, M.G., Vizzielli, G., et al. (2020) Randomized Trial of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy for Advanced Epithelial Ovarian Cancer (SCORPION-NCT01461850). International Journal of Gynecologic Cancer, 30, 1657-1664. https://doi.org/10.1136/ijgc-2020-001640
|
[10]
|
Copur M.S., Gauchan, D., Ramaekers, R., et al. (2017) Neoadjuvant Chemotherapy or Primary Debulking Surgery for Stage IIIC Ovarian Cancer. Journal of Clinical Oncology, 35, 802-803. https://doi.org/10.1200/JCO.2016.70.7125
|
[11]
|
Wright, A.A., Bohlke, K., Armstrong, D.K., et al. (2016) Neoad-juvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Gynecologic Oncology, 143, 3-15. https://doi.org/10.1016/j.ygyno.2016.05.022
|
[12]
|
Narasimhulu, D.M., Kumar, A., Weaver, A.L., et al. (2019) Us-ing an Evidence-Based Triage Algorithm to Reduce 90-Day Mortality after Primary Debulking Surgery for Advanced Epithelial Ovarian Cancer. Gynecologic Oncology, 155, 58-62. https://doi.org/10.1016/j.ygyno.2019.08.004
|
[13]
|
Kang, S., Kim, T.J., Nam, B.H., et al. (2010) Preoperative Serum CA-125 Levels and Risk of Suboptimal Cytoreduction in Ovarian Cancer: A Meta-Analysis. The Journal of Surgical Oncology, 101, 13-17.
https://doi.org/10.1002/jso.21398
|
[14]
|
Chi, D.S., Venkatraman, E.S., Masson, V., et al. (2000) The Ability of Preoperative Serum CA-125 to Predict Optimal Primary Tumor Cytoreduction in Stage III Epithelial Ovarian Carcinoma. Gynecologic Oncology, 77, 227-231.
https://doi.org/10.1006/gyno.2000.5749
|
[15]
|
李胜霞, 朱晨辰, 张安娜, 等. CA125动力学变化预测新辅助化疗晚期卵巢癌患者满意减瘤临床分析[J]. 现代妇产科进展, 2022, 31(10): 745-750.
|
[16]
|
Fleming, N.D., Westin, S.N., Rauh-Hain, J.A., et al. (2021) Factors Associated with Response to Neoadjuvant Chemotherapy in Advanced Stage Ovarian Cancer. Gynecologic Oncology, 162, 65-71.
https://doi.org/10.1016/j.ygyno.2021.04.002
|
[17]
|
Shen, Y. and Li, L. (2016) Serum HE4 Superior to CA125 in Predicting Poorer Surgical Outcome of Epithelial Ovarian Cancer. Tumor Biology, 37, 14765-14772. https://doi.org/10.1007/s13277-016-5335-0
|
[18]
|
Aithal, A., Rauth, S., Kshirsagar, P., et al. (2018) MUC16 as a Novel Target for Cancer Therapy. Expert Opinion on Therapeutic Targets, 22, 675-686. https://doi.org/10.1080/14728222.2018.1498845
|
[19]
|
Felder, M., Kapur, A., Gonzalez-Bosquet, J., et al. (2014) MUC16 (CA125): Tumor Biomarker to Cancer Therapy, a Work in Progress. Molecular Cancer, 13, Article No. 129. https://doi.org/10.1186/1476-4598-13-129
|
[20]
|
Galgano, M.T., Hampton, G.M., Frierson, H.J. (2006) Compre-hensive Analysis of HE4 Expression in Normal and Malignant Human Tissues. Modern Pathology, 19, 847-853. https://doi.org/10.1038/modpathol.3800612
|
[21]
|
Desbene, C., Maiga, R.Y. and Gaillard, O. (2018) Caractéristiques Immunoanalytiques de la protéine HE4. Annales de Biologie Clinique, 76, 225-233. https://doi.org/10.1684/abc.2018.1330
|
[22]
|
Hellstrom, I., Raycraft, J., Hayden-Ledbetter, M., et al. (2003) The HE4 (WFDC2) Protein Is a Biomarker for Ovarian carcinoma. Cancer Research, 63, 3695-3700.
|
[23]
|
Buamah, P. (2000) Benign Conditions Associated with Raised Serum CA-125 Concentration. Journal of Surgical Oncology, 75, 264-265. https://doi.org/10.1002/1096-9098(200012)75:4<264::AID-JSO7>3.0.CO;2-Q
|
[24]
|
Olsen, M., Lof, P., Stiekema, A., et al. (2021) The Diagnostic Accuracy of Human Epididymis Protein 4 (HE4) for Discriminating between Benign and Malignant Pelvic Masses: A Systematic Review and Meta-Analysis. Acta Obstetricia et Gynecologica Scan-dinavica, 100, 1788-1799. https://doi.org/10.1111/aogs.14224
|
[25]
|
Tangjitgamol, S., Manusirivithaya, S., Laopai-boon, M., et al. (2013) Interval Debulking Surgery for Advanced Epithelial Ovarian Cancer. Cochrane Database of Sys-tematic Reviews, 4, D6014.
https://doi.org/10.1002/14651858.CD006014.pub6
|
[26]
|
Harter, P., Muallem, Z.M., Buhrmann, C., et al. (2011) Impact of a Structured Quality Management Program on Surgical Outcome in Primary Advanced Ovarian Cancer. Gyne-cologic Oncology, 121, 615-619.
https://doi.org/10.1002/14651858.CD006014.pub6
|
[27]
|
Pelissier, A., Roulot, A., Guéry, B., Bonneau, C., Bellet, D. and Rouzier, R. (2016) Serum CA125 and HE4 Levels as Predictors for Optimal Interval Surgery and Platinum Sen-sitivity after Neoadjuvant Platinum-Based Chemotherapy in Patients with Advanced Epithelial Ovarian Cancer. Journal of Ovarian Research, 9, Article No. 61.
https://doi.org/10.1186/s13048-016-0270-7
|
[28]
|
Ataseven, B., du Bois, A., Reinthaller, A., Traut, A., et al. (2015) Pre-Operative Serum Albumin Is Associated with Post-Operative Complication Rate and Overall Survival in Patients with Epithelial Ovarian Cancer Undergoing Cytoreductive Surgery. Gynecologic Oncology, 138, 560-565. https://doi.org/10.1016/j.ygyno.2015.07.005
|
[29]
|
赵云平, 张国楠. 血清白蛋白对晚期卵巢癌NACT-IDS治疗模式的影响[J]. 肿瘤预防与治疗, 2017, 30(3): 232-237.
|
[30]
|
Parker, D., Bradley, C., Bogle, S.M., et al. (1994) Se-rum Albumin and CA125 Are Powerful Predictors of Survival in Epithelial Ovarian Cancer. British Journal of Obstetrics and Gynaecology, 101, 888-893.
https://doi.org/10.1111/j.1471-0528.1994.tb13550.x
|